Venus Remedies is currently trading at Rs. 264.35, up by 4.55 points or 1.75% from its previous closing of Rs. 259.80 on the BSE.
The scrip opened at Rs. 259.90 and has touched a high and low of Rs. 276.90 and Rs. 252.55 respectively. So far 56,986 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 358.05 on 15-May-2013 and a 52 week low of Rs. 196.95 on 26-Jul-2012.
Last one week high and low of the scrip stood at Rs. 271.00 and Rs. 249.20 respectively. The current market cap of the company is Rs. 257 crore.
The promoters holding in the company stood at 39.21%, while Institutions and Non-Institutions held 13.27% and 47.52% respectively.
Venus Remedies has received patent from the Japanese Patent Office for Elores, the Antibiotic against Superbugs. The company is expecting to launch this product in Japanese market by end of 2015. Elores was launched in Indian market in January this year and has received tremendous response from medical fraternity.
Elores has a unique profile of action which gives it an edge over all the existing therapies. This unique antibiotics adjuvant entity creates a synergistic effect due to its activity on Muli-drug resistant ESBL/MBL producing gram negative bacteria. lt not only kills resistant pathogens but also prevents spread of resistance.
Venus Remedies is a pharmaceutical manufacturing company. The company provides formulations in area of antibiotics and oncological therapeutics. The company has two manufacturing facilities located in India and Germany. It manufactures Oncological and Cefelosporine Injectable products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: